Equities

ImmuPharma PLC

IMM:LSE

ImmuPharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2.08
  • Today's Change-0.05 / -2.35%
  • Shares traded936.69k
  • 1 Year change-0.95%
  • Beta2.5162
Data delayed at least 20 minutes, as of Jun 28 2024 16:12 BST.
More ▼

Profile data is unavailable for this security.

About the company

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-2.92m
  • Incorporated2000
  • Employees5.00
  • Location
    ImmuPharma PLCOne Bartholomew CloseLONDON EC1A 7BLUnited KingdomGBR
  • Phone+44 20 7152 4080Fax+44 20 7152 4001
  • Websitehttps://www.immupharma.co.uk/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
BSF Enterprise PLC67.24k-1.71m5.43m4.005.43m4.00
Cizzle Biotechnology Holdings PLC0.00-1.72m6.74m67.006.74m67.00
Synairgen plc0.00-8.41m7.70m30.007.70m30.00
Oncimmune Holdings PLC1.21m-3.19m8.27m56.008.27m56.00
ImmuPharma PLC0.00-2.92m8.87m5.008.87m5.00
Kanabo Group PLC895.00k-7.99m9.17m20.009.17m20.00
Genflow Biosciences PLC0.00-1.63m9.27m5.009.27m5.00
Destiny Pharma PLC0.00-5.66m9.29m19.009.29m19.00
Bivictrix Therapeutics PLC0.00-2.55m10.30m12.0010.30m12.00
Chill Brands Group PLC146.62k-3.64m10.89m2.0010.89m2.00
Genincode PLC2.16m-7.02m11.95m36.0011.95m36.00
Proteome Sciences plc5.03m-2.44m12.25m35.0012.25m35.00
Abingdon Health PLC5.34m-2.24m12.99m82.0012.99m82.00
Data as of Jun 28 2024. Currency figures normalised to ImmuPharma PLC's reporting currency: UK Pound GBX

Institutional shareholders

31.67%Per cent of shares held by top holders
HolderShares% Held
KW Investment Management Ltd.as of 03 Jun 202455.71m13.38%
Hargreaves Lansdown Asset Management Ltd.as of 03 Jun 202423.26m5.59%
Chelverton Asset Management Ltd.as of 30 Jun 202315.00m3.60%
HSBC Global Asset Management (UK) Ltd.as of 03 Jun 202413.39m3.22%
IG Markets Ltd.as of 03 Jun 202412.01m2.88%
Bank J. Safra Sarasin AG (Investment Management)as of 03 Jun 20243.25m0.78%
Jarvis Investment Management Ltd.as of 03 Jun 20242.39m0.57%
HSBC Bank Plc (Market-Maker)as of 03 Jun 20242.35m0.57%
iDealing.com Ltd.as of 03 Jun 20242.30m0.55%
Close Asset Management Ltd.as of 03 Jun 20242.23m0.54%
More ▼
Data from 30 Sep 2023 - 03 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.